Actively Recruiting
MCT for the Harvard/UCSF ROBIN Center
Led by Brigham and Women's Hospital · Updated on 2025-02-17
47
Participants Needed
2
Research Sites
258 weeks
Total Duration
On this page
Sponsors
B
Brigham and Women's Hospital
Lead Sponsor
D
Dana-Farber Cancer Institute
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of the Molecular Characterization Trial (MCT) is to obtain biological specimens and data resources from patients enrolled on prospective trials, to ensure that the Harvard/UCSF ROBIN Center accomplishes its key objective of advancing our understanding of the biological mechanisms that underlie how radiation treats tumors but also can cause unwanted side effects. The MCT focuses on collection of research biospecimens before, during, and after radiation. Also critical to the MCT is the deep annotation of these research biospecimens with elements that complement each other to provide a holistic, detailed view of each patient. Annotated elements include those used in the past such as clinical and biological features but extend to factors we have so far neglected but must incorporate in the future such as dosimetry (precise anatomical measurement of radiation dose), artificial intelligence, computational biology, and natural language processing.
CONDITIONS
Official Title
MCT for the Harvard/UCSF ROBIN Center
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Enrollment in either PNOC023 trial for diffuse midline glioma or ANBL1531 trial for high-risk neuroblastoma
- Newly diagnosed diffuse midline glioma, age 2 years or older, with stable or decreasing corticosteroid use if applicable
- Karnofsky score of 50 or higher for ages over 16, or Lansky score of 50 or higher for ages 16 and under
- No known immune system disorder or uncontrolled infection for PNOC023 participants
- Diagnosis of high-risk neuroblastoma according to specific staging and genetic criteria for ANBL1531
- Age between 1 and 30 years at diagnosis for ANBL1531
- No prior systemic or radiation therapy except allowed exceptions for ANBL1531
- No contraindication to targeted radiopharmaceutical therapy for ANBL1531
- Confirmation of tumor malignancy by tissue diagnosis
- Adequate bone marrow, kidney, liver, and neurological function
- Availability of tumor tissue, blood, and/or cerebrospinal fluid samples
You will not qualify if you...
- Pregnancy or breastfeeding
- Inability to follow study procedures
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
University of California, San Francisco
San Francisco, California, United States, 94143
Actively Recruiting
2
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Actively Recruiting
Research Team
D
David Kozono, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here